GLP-1 Drugs and Muscle Loss: Retatrutide for Lean Australians (2025)

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice. ProtocolHub may earn affiliate commissions from partner referrals — this does not affect our editorial recommendations.

In the STEP 1 semaglutide trial, roughly 35% of the total weight lost was lean mass — not fat. For someone losing 30 kg of excess body fat, losing 5 kg of muscle alongside it is a tolerable trade. For someone who is already lean and has spent five years building 15 kg of muscle, that number is a catastrophe. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist in Phase 3 clinical trials — designed specifically for superior body composition outcomes. It is not yet TGA-approved in Australia. This article covers what the evidence shows, why it matters for lifters, and the short-cycle protocol Australian practitioners are using right now to preserve lean mass on currently accessible compounds.

Note: Retatrutide's approval status may have changed since this article was published. Verify the current TGA status before discussing with a prescriber.

Why do GLP-1 drugs eat muscle — and why does it matter for lean people?

The lean mass loss data is consistent across semaglutide trials:

STEP 1 (semaglutide 2.4 mg/week): average 14.9% total weight loss over 68 weeks. Of the weight lost, approximately 35% was lean mass — around 4–5 kg of muscle for a typical participant.
SURMOUNT-1 (tirzepatide 15 mg/week): average 20.9% total weight loss. Lean mass loss proportion was lower — approximately 26–28% — suggesting the GIP receptor component provides some lean mass preservation advantage.

Why does it happen? GLP-1 agents suppress appetite significantly — reducing caloric intake by 30–40%. When calories drop sharply without aggressive protein and resistance training intervention, the body enters a catabolic state and preferentially catabolises lean tissue alongside fat. The drug provides the caloric deficit; the protocol determines what comes out of it.

For someone carrying 30 kg of excess fat, losing 5 kg of muscle is a tolerable exchange for 25 kg of fat loss. For a lean 85 kg lifter with 10% body fat carrying 8.5 kg of total fat, the math looks completely different. Losing 35% of any weight as muscle when there isn't much fat to lose risks stripping the physique that took years to build.

What makes retatrutide different — and why the strength community is watching Phase 3 trials

Retatrutide (LY3437943) is Eli Lilly's next-generation GLP-1 agent — a triple GIP/GLP-1/glucagon receptor agonist, adding glucagon agonism to the dual mechanism of tirzepatide.

The triple mechanism:

GLP-1 agonism — appetite suppression, gastric emptying slowdown, insulin secretion modulation (same as semaglutide)
GIP agonism — enhances GLP-1 efficacy, direct adipose tissue effects, potential lean mass preservation signal (same as tirzepatide)
Glucagon agonism — the new piece. Glucagon activates brown adipose tissue thermogenesis — the body burns more energy at rest, primarily from fat stores. This thermogenic component means the caloric deficit is achieved partly through increased expenditure, not purely appetite suppression. The implication for body composition: if the energy gap is filled by burning fat rather than solely by eating less, the lean mass sparing is theoretically better.

Phase 2 data (TRIUMPH Phase 2 trial, 2023): At the highest dose (24 mg/week over 48 weeks), participants averaged 24.2% body weight reduction. The body composition data from Phase 2 is promising — suggesting a more favourable lean mass to fat mass loss ratio than semaglutide. But Phase 2 body composition data is not Phase 3-confirmed. The lean mass preservation story is still being written.

The honest evidence position: Phase 2 data is encouraging, not conclusive. Evidence level for retatrutide's body composition advantage over semaglutide: emerging. Phase 3 lean mass data is what the scientific community — and the strength community — is waiting for.

Can you get retatrutide in Australia right now?

No — and the reason is important to understand.

Retatrutide is in Phase 3 clinical trials as of mid-2025. It has not received FDA approval (the regulatory decision that typically precedes TGA review by 6–18 months). Without FDA approval, there is no established TGA review pathway. Without TGA review, there is no approved product and no compounding pathway for this specific molecule.

Unlike tirzepatide — which has TGA approval for Type 2 diabetes and can be compounded off-label for weight management — retatrutide has no Australian approval at all. A licensed compounding pharmacy cannot prepare a compound for which no regulatory pathway exists.

What would need to happen for access: FDA approval → TGA application (Eli Lilly would need to apply) → TGA review (6–18 months) → TGA approval → then, potentially, compounded versions could follow. Optimistic timeline: 2026–2027 for any Australian access pathway.

Verify the current status before discussing with a prescriber — this is a rapidly evolving regulatory landscape.

What lean Australian lifters can access right now — and why tirzepatide is the closest option

Compare Australian clinics offering GLP-1 body composition programs →

ProtocolHub earns a commission when you visit partner links. This does not affect our recommendations.

Tirzepatide (off-label compounded) — $180–$380 AUD/month

The dual GIP/GLP-1 mechanism covers two of retatrutide's three agonist targets. The GIP component is the key — SURMOUNT-1 data shows ~26–28% lean mass loss vs semaglutide's ~35%, suggesting real body composition advantage. Available off-label via Australian telehealth clinics with AHPRA prescription + licensed compounding pharmacy.

For a lean lifter, tirzepatide is the current best available option while retatrutide trials complete. Discuss explicitly with your prescriber that you are lean, that lean mass preservation is the primary goal, and that you want a short-cycle approach rather than continuous dosing.

Semaglutide (TGA-approved, Wegovy) — $129–$320 AUD/month

Accessible, approved, and evidence-rich — but the highest lean mass loss risk of the available options. If semaglutide is the only practical option, the short-cycle protocol below becomes even more important. Continuous dosing without the muscle preservation overlay is where lean mass loss accumulates.

AOD-9604 (lipolysis only) — $180–$280 AUD/month

Different mechanism entirely — no appetite suppression, directly targets fat cells via lipolysis. For a very lean individual (sub-12% body fat) who wants targeted fat removal without appetite effects and without any lean mass risk, AOD-9604 is the most appropriate choice. Does not produce the scale weight changes of GLP-1 agents but produces meaningful body composition changes over a 12-week cycle.

Ipamorelin + CJC-1295 — $150–$250 AUD/month

Not a fat-loss compound directly. Supports GH axis and lean mass retention during and between GLP-1 cycles. Particularly valuable during off-cycle periods to preserve the muscle built. Some practitioners run it concurrently with GLP-1 agents for the lean mass protection signal.

The short-cycle protocol for lean lifters — how to preserve muscle on any GLP-1 agent

This section is the practical framework. Every lean lifter who reads it will use it.

Cycle duration and the off-cycle recovery window

8–12 weeks on / minimum 8 weeks off. Not continuous dosing.

The standard clinical protocol for obesity management uses continuous dosing — the goal is sustained appetite suppression for prolonged weight loss. For a lean individual using a GLP-1 agent for body recomposition, this is wrong. Continuous GLP-1 use in a lean person creates cumulative lean mass depletion over multiple cycles. Each cycle starts from a lower lean mass baseline.

The off-cycle window allows: caloric restoration to maintenance, muscle protein synthesis recovery, hormonal normalisation (GH axis, testosterone), and psychological recovery from appetite suppression.

On-cycle caloric target: mild deficit only — 200–300 kcal below TDEE maximum. The compound provides the fat loss mechanism; do not add aggressive dietary restriction on top.

Off-cycle target: return to maintenance or slight surplus (100–200 kcal above TDEE). Prioritise muscle recovery and glycogen restoration.

This is a body composition protocol, not an obesity treatment protocol. Discuss the short-cycle approach explicitly with your AHPRA prescriber before starting.

The protein and resistance training overlay — the non-negotiable layer

Protein: 2.2–2.6 g/kg bodyweight per day throughout the cycle. This is non-negotiable. GLP-1 agents suppress total caloric intake — the risk is protein intake dropping proportionally with total calories. Track protein actively on cycle.

Leucine: 3–5 g with each main meal. Leucine is the primary amino acid that activates mTOR — the signalling pathway for muscle protein synthesis. Available OTC at Australian supplement retailers. Take with the meal, not separately.

Creatine: 5 g/day throughout cycle and off-cycle without interruption. The evidence for creatine in lean mass preservation is exceptional — continue regardless of cycle status.

Resistance training: maintain compound movement volume. Squat, deadlift, press, row — do not reduce significantly on cycle. The mechanical stimulus from heavy training is the primary signal telling the body to preserve lean mass. Removing it during GLP-1 use accelerates muscle catabolism. If appetite suppression reduces training energy, reduce cardio before reducing resistance training volume.

The monitoring protocol

DEXA scan: baseline before the first cycle, repeat at end of the 8–12 week cycle. DEXA measures lean mass and fat mass independently — it is the only objective measure of whether the protocol is working. Body weight is a misleading metric for lean individuals. You may lose 2–3 kg of fat and gain 0.5 kg of muscle and the scale barely moves. DEXA shows the truth.

Australian DEXA scan cost: $80–$150 at private radiology (IDoImaging, Capitol Radiology, and others). Not Medicare-rebatable for body composition purposes.

Blood markers: IGF-1, testosterone (free + total), SHBG — test at baseline and end of cycle. GLP-1 agents can affect these markers. If testosterone drops significantly on cycle, discuss with your prescriber.

What are the risks specific to lean, muscular individuals?

Muscle loss — the primary risk, addressed throughout this article. Protocol mitigates this substantially but does not eliminate it.

Relative energy deficiency (RED-S): Lean athletes with already optimised caloric intake running GLP-1 agents can drop below energy availability thresholds. Monitor total caloric intake carefully — below 30 kcal/kg lean mass/day triggers RED-S.

GI side effects: More pronounced in lean individuals at standard starting doses. Start at the lowest available dose and titrate more slowly than the standard protocol. Your prescriber should accommodate this request.

The honest limitation: No published RCTs exist specifically for lean, resistance-trained individuals using GLP-1 agents for body recomposition. Everything in this section is based on mechanism reasoning, body composition trial sub-analyses, and practitioner experience with this population. State this clearly to yourself and to your prescriber.

How to find an Australian prescriber who understands the lean lifter protocol

Standard weight loss clinics run standard weight loss protocols. That's appropriate for their primary patient population — it is not appropriate for a lean lifter.

What to say at your consultation: "I am already lean and my goal is body recomposition — reducing fat while preserving lean mass. I want to discuss a short-cycle approach with DEXA monitoring, not continuous weight management dosing. Lean mass preservation is the primary success metric."

Clinics whose practitioners are likely to engage with this: Thrive Rx (blood panel included, biomarker-led model, ongoing monitoring) and BioV8 (specialist peptide clinic with body composition focus).

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice.

GLP-1 Drugs Eat Muscle. Retatrutide Was Designed to Change That — Here's What Lean Australian Lifters Need to Know Right Now